검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 5-aminosalicylic acid (5-aminosalicylic acid) Merck Sharp & Dohme LLC·Colitis, Ulcerative 78 trials·t½ 8.2 h |
|---|---|
Overview Program | 5-aminosalicylic acid |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Colitis, Ulcerative |
Overview Indication | Colitis, Ulcerative |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | target protective effects against experimental colitis by modulating inflammation, supporting barrier integrity, and regulating key signaling pathway |
MoA Biomarker | Biomarker-Guided, Patient-Centered Approach |
PK/PD Half-life | 8.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | 4-DMB, a diclofenac derivative, alleviates DSS-induced ulcerative colitis in mice by binding TNFR1 to inhibit inflammation.. Novel diclofenac (Dic) hybrids with methyl 2-bromobenzoate (2-DMB) and methyl 4-bromobenzoate (4-DMB) modifications via ester linkages have been synthesized and proven to have anti-inflammatory potential in vitro, suggesting that further development of these compounds may le… |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 5-aminosalicylic acid (5-aminosalicylic acid) Merck Sharp & Dohme LLC·Colitis, Ulcerative 78 trials·t½ 8.2 h |
|---|---|
Overview Program | 5-aminosalicylic acid |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Colitis, Ulcerative |
Overview Indication | Colitis, Ulcerative |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | target protective effects against experimental colitis by modulating inflammation, supporting barrier integrity, and regulating key signaling pathway |
MoA Biomarker | Biomarker-Guided, Patient-Centered Approach |
PK/PD Half-life | 8.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | 4-DMB, a diclofenac derivative, alleviates DSS-induced ulcerative colitis in mice by binding TNFR1 to inhibit inflammation.. Novel diclofenac (Dic) hybrids with methyl 2-bromobenzoate (2-DMB) and methyl 4-bromobenzoate (4-DMB) modifications via ester linkages have been synthesized and proven to have anti-inflammatory potential in vitro, suggesting that further development of these compounds may le… |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교